• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol Methods. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses.

Giuseppe

Emeritus
J Virol Methods. 2008 Aug 18. [Epub ahead of print]

Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses.

Carr MJ, Sayre N, Duffy M, Connell J, Hall WW. - National Virus Reference Laboratory, University College Dublin, Belfield, Dublin 4, Ireland.

The neuraminidase inhibitor (NAI), oseltamivir has been stockpiled around the world as an antiviral therapeutic option for an anticipated influenza pandemic.

In early 2008, drug susceptibility surveillance of influenza viruses in Europe revealed that some influenza A viruses (subtype H1N1) circulating during the winter season of 2007 and 2008 were resistant to the NAI, oseltamivir.

The genetic marker of viral drug resistance arises through a cytosine to thymine mutation in the influenza A/H1N1 neuraminidase 1 gene resulting in a histidine to tyrosine substitution at amino acid position 275 in the sialidase active site (H275Y in N1 nomenclature).

Current methods to detect this mutation involve an end-point reverse transcription polymerase chain reaction followed by nucleotide sequencing.

While accurate, this approach has the limitation of being time-consuming, labour-intensive and expensive.

PMID: 18718489 [PubMed - as supplied by publisher
-
http://www.ncbi.nlm.nih.gov/pubmed/18718489
------
 
Back
Top